Fischer Medical Ventures Approves Rights Issues in Subsidiaries
Fischer Medical Ventures' Board approved rights issues for subsidiaries Time Medical, Flynn Care, and FMV Global. The company will invest in these rights issues. Time Medical issued shares at ₹7,370.25, Flynn Care at ₹82,943.48, and FMV Global at ₹48,83,552.64.
The investment in subsidiaries through rights issues can lead to improved financial performance and operational capabilities, impacting the overall business.
The company is investing in its subsidiaries through rights issues, which indicates growth and expansion plans.
Fischer Medical Ventures Limited's Board of Directors, in a meeting held on September 24, 2026, approved rights issues by its material unlisted subsidiary companies. Time Medical International Ventures (India) Private Limited, a wholly owned subsidiary, issued 15,603 equity shares at ₹7,370.25 per share. Flynn care Health Innovations Private Limited, another wholly owned subsidiary, issued 1,507 equity shares at ₹82,943.48 per share. Additionally, FMV Global Innovation Pte. Ltd., also a wholly owned subsidiary, issued 53 equity shares at ₹48,83,552.64 per share.
The Board also approved the company's investment in these rights issues by subscribing to the equity shares offered by its subsidiaries: Time Medical International Ventures (India) Private Limited, FlynnCare Health Innovations Private Limited, and FMV Global Innovation Pte. Ltd. These transactions are conducted at arm's length and supported by valuation reports.
Time Medical International Ventures (India) Private Limited, incorporated on January 10, 2019, is involved in the medical diagnostic imaging industry, focusing on developing and providing affordable medical imaging solutions, including MRI systems. Its turnover for FY 2025-26 was ₹5,500.50 lakhs. FlynnCare Health Innovations Private Limited, incorporated on July 29, 2024, operates in the digital healthcare space, offering end-to-end solutions through a Digital Hospital platform and community care solutions. Its turnover for FY 2025-26 was ₹8,629.26 lakhs. FMV Global Innovation Pte. Ltd., incorporated on July 1, 2024, is engaged in the wholesale, marketing, and sale of medical, professional, scientific, and precision equipment, supporting the Group's international medical technology business.
What to do with a filing like this
Fischer Medical Ventures Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fischer Medical Ventures Limited. Read the original for the full detail.